Join the club for FREE to access the whole archive and other member benefits.

Adicet merges with resTorbio for CAR T-cell therapy pipeline funding

The deal moves company forward to initiating phase 1 trials in non-Hodgkin lymphoma next year


Key points from article :

Adicet Bio has struck a deal to merge with resTORbio, bagging itself a Nasdaq listing.

The deal will see Adicet land a spot on Nasdaq without going the IPO route.

Investment will fund development of a cell therapy pipeline led by anti-CD20 prospect ADI-001.

The combined company will take Adicet’s name and focus on its pipeline.

It will be led by resTORbio CEO Chen Schor.

Shareholders in Adicet will own 75% of the combined company.

IND-enabling activities in support of ADI-001 are underway.

Phase 1 trial underway, expected to deliver clinical data next year.

To reveal whether the tumor control Adicet saw in mice translates into humans.

And to validate Adicet’s belief it has a differentiated, off-the-shelf cell therapy platform.

Mentioned in this article:

Click on resource name for more details.

Adicet Bio

Biotechnology company

Chen Schor

Founder, President, CEO, Secretary & Director, resTORbio, Inc.

Johnson & Johnson

Largest healthcare company that develops medical devices, pharmaceuticals, and consumer packaged goods


Financial services company


Global medicines company for developing and producing drugs.

OrbiMed Advisors

Capital market company

Regeneron Pharmaceuticals

Biotechnology company


Biopharmaceutical company developing therapeutics for aging-related diseases.

Topics mentioned on this page: